[Retracted] Analysis of Clinical Characteristics and Risk Factors of Postoperative Recurrence and Malignant Transformation of Low-Grade Glioma

Table 5

Single factor analysis of recurrence and malignant transformation in the Obs group.

Type	Cases of recurrence and malignant transformation	Mean time to recurrence and malignant transformation (months)	t	P
Sex
Male	14	21.69 ± 2.13	−0.081c	0.987
Female	5	23.56 ± 1.58
Age
≤45	7	24.23 ± 2.54	−0.795	0.524
>45	12	21.77 ± 2.36
Preoperative KPS score
<80	6	15.02 ± 2.13	4.846	0.046
≥80	13	22.67 ± 2.61
Preoperative duration of disease (month)
≤3	5	15.13 ± 1.54	4.563	0.003
3–6	7	13.61 ± 2.99
>6	7	9.75 ± 3.32
Tumor site
Half of the brain	13	19.86 ± 2.31	0.522	0.087
Others	6	14.12 ± 2.04
Tumor size (cm)
≤5	9	23.75 ± 3.46	0.565	0.325
>5	10	20.91 ± 2.78
Surgical resection range
Total resection	4	20.05 ± 2.06	11.042	0.036
Subtotal resection	7	18.47 ± 2.35
Local total resection	8	13.32 ± 2.89
Postoperative KPS score
<80	8	10.02 ± 2.54	0.786	0.261
≥80	11	12.58 ± 2.96
Preoperative epilepsy
Yes	3	12.35 ± 1.86	0.092	0.872
No	16	10.78 ± 2.05
Postoperative treatment
Radiation therapy	9	9.56 ± 2.16	3.746	0.023
Chemotherapy	7	10.48 ± 1.88
Radiotherapy + chemotherapy	3	13.59 ± 2.04
PCNA expression
Negative	1	14.12 ± 2.84	3.976	0.031
Positive	11	11.04 ± 3.10
Strong positive	7	8.67 ± 2.55
MMP-9 expression
Positive	8	12.83 ± 3.56	0.495	0.043
Strong positive	11	9.86 ± 3.28
OY-TES-1 protein expression
Negative	11	20.62 ± 2.43	3.562	<0.001
Positive	8	27.54 ± 2.61
OY-TES-1 mRNA protein expression
Negative	10	19.85 ± 2.79	3.336	<0.001
Positive	9	26.93 ± 3.15
P53
Negative	2	23.41 ± 2.09	2.875	0.003
Positive	17	11.26 ± 2.54
MDM2
Negative	4	22.43 ± 3.24	3.594	0.026
Positive	15	16.68 ± 3.38
VEGF
Negative	8	19.64 ± 3.08	3.119	0.009
Positive	11	15.44 ± 2.61
EGFR
Negative	2	20.15 ± 2.87	2.967	0.043
Positive	17	13.47 ± 2.64